DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service

Food and Drug Administration
Rockville MD 20857

NDA 50-207/S-057
NDA 50-297/S-019
NDA 50-611/S-019

Abbott Laboratories
Pharmaceutical Products Division
Attention: Alexa L. Chun, Ph.D.
Associate Director
100 Abbott Park Road
D-491, AP6B-1SW
Abbott Park, IL 60064-6108

Dear Dr. Chun:

Please refer to your supplemental new drug applications dated June 26, 2000, received June 27, 2000, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for:

NDA 50-207 for E. E. S.® Granules, EryPed® Drops, Ery Ped ® 200 and EryPed® 400 (erythromycin ethylsuccinate for oral suspension, USP

NDA 50-297 for EryPed ® (erytrhomycin ethylsuccinate tablets) Chewable Tablets

NDA 50-611 for PCE ® (erythormycin particles in tablets) Tablets.

We note that these applications are subject to the exemption provisions contained in section 125(d)(2) of Title I of the FDA Modernization Act of 1997.

We acknowledge receipt of your submissions dated May 31, 2001.

These supplemental new drug applications provide for

1. Revisions to the PRECAUTIONS section to include the information regarding the potential risk of Infantile Hypertrophic Pyloric Stenosis (IHPS) in the label of Abbott's erythromycin products.

2. Revisions to the PRECAUTIONS section to include interactions involving the cytochrome P450 system.

3. Revisions to the CONTRAINDICATIONS section to include "pimozide."

4. Revisions to the ADVERSE REACTIONS section to include revised wording regarding QT intervals, and addition of "pancreatitis" and "convulsion" as rare reports.

We have completed the review of these supplemental applications, as amended, and have concluded that adequate information has been presented to demonstrate that the drug products are safe and effective for use as recommended in the submitted labeling text and with the revisions listed below. Accordingly, these supplemental applications are approved effective on the date of this letter.

1. Revise the **PRECAUTIONS** section, *General* subsection, 3rd paragraph to read as follows.

   "There have been reports of infantile hypertrophic pyloric stenosis (IHPS) occurring in infants following erythromycin therapy. In one cohort of 157 newborns who were given erythromycin for pertussis prophylaxis, seven neonates (5%) developed symptoms of non-bilious vomiting or irritability with feeding and were subsequently diagnosed as having IHPS requiring surgical pyloromyotomy. A possible dose-response effect was described with an absolute risk of IHPS of 5.1% for infants who took erythromycin for 8-14 days and 10% for infants who took erythromycin for 15-21 days. Since erythromycin may be used in the treatment of conditions in infants which are associated with significant mortality or morbidity (such as pertussis or neonatal *Chlamydia trachomatis* infections), the benefit of erythromycin therapy needs to be weighed against the potential risk of developing IHPS. Parents should be informed to contact their physician if vomiting or irritability with feeding occurs."

2. In the **PRECAUTIONS** section, *Drug Interactions,* at the end of the *Sildenafil (Viagra)* subsection, capitalize the parenthetical phrase to read "(See Viagra package insert.)"

3. In the **PRECAUTIONS** section, *Drug Interactions* subsection, at the end of the 11th paragraph, capitalize the parenthetical phrase to read "(See **CONTRAINDICATIONS.**)"

The final printed labeling (FPL) must be identical to the submitted draft labeling (package insert submitted June 26, 2000) and include the revisions indicated above. These revisions are terms of the approval of these applications.

Please submit the copies of final printed labeling (FPL) electronically to each application according to the guidance for industry titled *Providing Regulatory Submissions in Electronic Format - NDA* (January 1999). Alternatively, you may submit 20 paper copies of the FPL as soon as it is available but no more than 30 days after it is printed. Please individually mount ten of the copies on heavy-weight paper or similar material. For administrative purposes, these submissions should be designated "FPL for approved supplemental NDAs 50-207/S-057, 50-297/S-019, 50-611/S-019." Approval of these submissions by FDA is not required before the labeling is used.

In addition, please submit three copies of the introductory promotional materials that you propose to use for these products. All proposed materials should be submitted in draft or mock-up form, not final print. Please submit one copy to this Division and two copies of both the promotional materials and the package inserts directly to:

Division of Drug Marketing, Advertising, and Communications, HFD-42
Food and Drug Administration
5600 Fishers Lane
Rockville, Maryland 20857

If a letter communicating important information about this drug product (i.e., a "Dear Health Care Professional" letter) is issued to physicians and others responsible for patient care, we request that you submit a copy of the letter to these NDAs and a copy to the following address:

MEDWATCH, HF-2
FDA
5600 Fishers Lane
Rockville, MD 20857

Please submit one market package of the drug product when it is available.

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, call Judit Milstein, Regulatory Project Manager, at (301) 827-2207.

Sincerely,

{See appended electronic signature page}

Janice M. Soreth, M.D.
Director
Division of Anti-Infective Drug Products
Office of Drug Evaluation IV
Center for Drug Evaluation and Research

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Janice Soreth

4/25/02 11:54:25 AM